Business
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and olderCompletes build-out of essential management operational infrastructure and hires 50 territory sales managers DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE)
About this update from Pelthos Therapeutics Inc.
[{"type":"image","alt":"Pelthos Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Pelthos Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yWW833l91CiuD7s17uRPhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355","width":300,"height":179}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and older","length":213,"tagName":"p"}]},{"val":[{"type":"text","content":"Completes build-out of essential management operational infrastructure and hires 50 territory sales managers","length":108,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":460,"olType":false},{"type":"text","content":"DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today reported financial results for legacy operations for the three and six months ended June 30, 2025. This will be the last set of financial results that the Company will issue solely related to the business operations of Channel Therapeutics Corporation prior to the consummation of the merger (the “Merger”) and the concurrent private placement financing that closed on July 1, 2025.","length":638,"tagName":"p"},{"type":"text","content":"Recent Company Highlights","length":25,"tagName":"p"},{"type":"text","content":"Completed the Merger with Channel Therapeutics and closed the $50.1 million private placement financing ","length":103,"tagName":"p"},{"type":"text","content":"As previously announced, on July 1, 2025, Pelthos completed its Merger with and into a wholly owned subsidiary of Channel Therapeutics Corporatio...